Amicus Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Amicus Therapeutics

31/07/2023 19:35

* Amicus Therapeutics Inc  FOLD.OQ   FOLD.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Philadelphia Pennsylvania-based  company is expected
to
report  a 11.3% increase in revenue to $89.868 million from
$80.73 million a year ago, according to the mean estimate from
10 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Amicus Therapeutics
Inc
is for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $16​, above​ its last closing price
of $13.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.16       -0.15      -0.18     Missed  -22.7
 Dec. 31 2023  -0.13       -0.13      -0.19     Missed  -50.4
 Sep. 30 2022  -0.19       -0.19      -0.12     Beat    35.6​
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    3.2
 ​​Mar.        -0.26       -0.25      -0.30     Missed  -17.6
 31 2022                                                
 Dec. 31 2021  -0.15       -0.16      -0.29     Missed  -85.9​
 Sep. 30 2021  -0.17       -0.17      -0.19     Missed  -13
 Jun. 30 2021  -0.22       -0.21      -0.19     Beat    10.1
 This summary was machine generated July 31 at 18:35 GMT.  All
figures in US dollars  unless otherwise stated